The Future of the ACA and Plans to Repeal: Dr Patricia Salber Interviews Dr Joe Antos

Transparency in Coverage Data to Expose Ghost Rates and Hold Payers Accountable: David Muhlestein, PhD

ACE inhibitors may improve survival in IPF patients, highlighting potential repurposing of a common cardiovascular drug.

January 20th 2026

Highlighting Gaps in Allergic Rhinitis Care, Allergen Immunotherapy Access

David Muhlestein, PhD, breaks down ghost rates, data gaps, and why stronger oversight is needed to make Transparency in Coverage files usable for patients.

Listen

Researchers identified 3 overarching themes: a prolonged journey with symptoms, multiple trials of therapy with inadequate control, and diverse experiences with AIT. | Image credit: Volha Zaitsava - stock.adobe.com

Managed Care Cast News Roundup: January 13, 2026

Patients with allergic rhinitis face prolonged symptoms and inadequate treatment, highlighting a need for better awareness and access to allergen immunotherapy.

January 13th 2026

Anlotinib Plus Chemotherapy Shows Promising Results in Advanced Soft Tissue Sarcoma

This week's news roundup covers updates in health policy, technology, and access to pharmaceuticals.

Listen

First-line anlotinib plus chemotherapy demonstrates favorable efficacy and manageable toxicity in advanced STS. | Image credit: @Aidman-Adobestock.jpeg

How ED Policies Can Better Protect Survivors of Violence: A Q&A With Prashasti Bhatnagar, Esq, MPH

Phase 2 trial results show anlotinib with anthracyclines and ifosfamide yields a 30.8% ORR and an 82.7% DCR in advanced soft tissue sarcoma.

A new study highlights how formalized, trauma-informed policies in emergency departments could better protect survivors of violence, said Prashasti Bhatnagar.

ACE Inhibitors Linked to Reduced Mortality in Patients with Idiopathic Pulmonary Fibrosis

A multistakeholder study explores how law enforcement presence in EDs affects survivors of violence and outlines trauma-informed, patient-centered policy solutions.

Related Content

January 26th 2026

Transparency in Coverage Data to Expose Ghost Rates and Hold Payers Accountable: David Muhlestein, PhD

ACE inhibitors may improve survival in IPF patients, highlighting potential repurposing of a common cardiovascular drug.

January 20th 2026

Highlighting Gaps in Allergic Rhinitis Care, Allergen Immunotherapy Access

David Muhlestein, PhD, breaks down ghost rates, data gaps, and why stronger oversight is needed to make Transparency in Coverage files usable for patients.

Listen

Managed Care Cast News Roundup: January 13, 2026

Patients with allergic rhinitis face prolonged symptoms and inadequate treatment, highlighting a need for better awareness and access to allergen immunotherapy.

January 13th 2026

Anlotinib Plus Chemotherapy Shows Promising Results in Advanced Soft Tissue Sarcoma

This week's news roundup covers updates in health policy, technology, and access to pharmaceuticals.

Listen

How ED Policies Can Better Protect Survivors of Violence: A Q&A With Prashasti Bhatnagar, Esq, MPH

Phase 2 trial results show anlotinib with anthracyclines and ifosfamide yields a 30.8% ORR and an 82.7% DCR in advanced soft tissue sarcoma.